Browse All

Current Filters

CLEAR FILTER x

TITLE

Program Number:

One-year Data from ENDEAVOR, a Phase 1b Trial of Delandistrogene Moxeparvovec (SRP-9001) in Patients with Duchenne Muscular Dystrophy (DMD)

Author:Zaidman, Craig   Proud, Crystal   McDonald, Craig   Mason, Stefanie   Guridi, Maitea   Wang, Shufang   Reid, Carol   Darton, Eddie   Wandel, Christoph   Lewis, Sarah   Malhotra, Jyoti   Griffin, Danielle   Potter, Rachael   Rodino-Klapac, Louise   Mendell, Jerry   

Session Name:S48: Therapeutics for Muscle Disease  

Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

Program Number:S48.003  

Author Institution:Department of Neurology, WUSTL, Washington, MO  Children’s Hospital of the King’s Daughters, Norfolk, VA  UC Davis Health, Sacramento, CA  Sarepta Therapeutics, Inc. , Cambridge, MA  F. Hoffmann-La Roche Ltd, Basel, Switzerland  Roche Products Ltd, Welwyn Garden City, United Kingdom  Center for Gene Therapy, Nationwide Children’s Hospital, Columbus, OH